TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32428369
Drug: Empiric classical
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empiric classical bismuth quadruple therapy
Study: 32428543
Drug: Nitric Oxide-Releasing
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide-Releasing Topical Medication
Study: 32429000
Drug: Gepotidacin 750
Normalized name: gepotidacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 750 mg IV over 2 hours
Study: 32429939
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy for BDD
Study: 32430018
Drug: Chia supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chia supplementation (25 g/day)
Study: 32430019
Drug: FACT-M questionnaire
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT-M questionnaire in treatment-naïve patients (Part B)
Study: 32430395
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9 mg/kg of body weight)
Study: 32430416
Drug: Daily FOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily FOT parameters (resistance (R) and reactance (X))
Study: 32430415
Drug: Microbiome-based therapies;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiome-based therapies; details on dosage and duration not available.
Study: 32430415
Drug: Host-targeted therapeutics;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Host-targeted therapeutics; details on dosage and duration not available.
Study: 32430583
Drug: Folic polyglutamate
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic polyglutamate tablets (oral) and 500 mL of a 10% mannitol solution (intravenous) before the injection of 3.7-5.5 GBq of radioligand therapy (RLT)
Study: 32430583
Drug: Radioligand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy (RLT) with 3.7-5.5 GBq
Study: 32435020
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor (C1-INH) 1000U administered biweekly via intravenous infusion
Study: 32435020
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor (C1-INH)
Study: 32436060
Drug: PF-06840003 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06840003 (500 mg BID)
Study: 32436060
Drug: PF-06840003 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06840003 (various doses)
Study: 32436335
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 12 weeks
Study: 32436335
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg/d) plus Daclatasvir with or without Ribavirin (1-1.2 g/d) for 24 weeks
Study: 32436923
Drug: sTILs as
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sTILs as an integral biomarker in a single-center phase II immunotherapy trial (TONIC trial, NCT02499367).
Study: 32437557
Drug: dihydroartemisinin/piperaquine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Study: 32437557
Drug: artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate monotherapy followed by dihydroartemisinin/piperaquine (4 mg/kg/day for 3 days)
Study: 32437664
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg flat dose IV) + Trastuzumab (8 mg/kg loading dose IV) + chemotherapy
Study: 32437664
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Trastuzumab + chemotherapy
Study: 32437738
Drug: Midostaurin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin treatment
Study: 32439432
Drug: Low-dose capsaicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose capsaicin (0.01 mM) nasal spray
Study: 32439432
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for idiopathic rhinitis
Study: 32439700
Drug: iNeo-Vac-P01 (neoantigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNeo-Vac-P01 (neoantigen vaccine)
Study: 32440228
Drug: Ethinylestradiol 20
Normalized name: Ethinylestradiol 20 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 20 μg/Drospirenone 3 mg
Study: 32440228
Drug: Post-treatment SF-36v2
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment SF-36v2 scores
Study: 32441892
Drug: Low-dose apatinib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose apatinib (500 mg or 250 mg per day)
Study: 32442637
Drug: Comparator software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator software solutions
Study: 32442785
Drug: Oral rigosertib
Normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rigosertib (140 mg twice daily, 280 mg twice daily, or 840 mg/day [560 mg morning/280 mg evening]) for 3 weeks of a 4-week cycle
Study: 32442785
Drug: Parenteral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Parenteral azacitidine (75 mg/m2)
Study: 32443041
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) performed between 2.5 and 3.5 months of age.
Study: 32443041
Drug: Abnormal OGTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abnormal OGTT defined as early hyperglycaemia (>1.8 g/L until 30 minutes; >1.7 g/L between 30 minutes and 2 hours; and >1.4 g/L between 2 and 3 hours) and/or late hypoglycaemia (<0.6 g/L after 2 hours).
Study: 32444192
Drug: Direct venous
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct venous inoculation (DVI) of PfSPZ Vaccine (0.5 mL)
Study: 32444192
Drug: Direct venous
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct venous inoculation (DVI) of PfSPZ Vaccine
Study: 32444241
Drug: Daily multivitamin/micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multivitamin/micronutrients supplement
Study: 32444411
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation with ferric maltol
Study: 32444417
Drug: Cediranib plus
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib plus Olaparib (Olaparib 300 mg twice daily + Cediranib 20 mg once daily)
Study: 32445848
Drug: Prolonged hospitalization,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged hospitalization, smoking, and preoperative opioid prescriptions
Study: 32446108
Drug: Sertraline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline + Prolonged Exposure (SERT + PE)
Study: 32446108
Drug: Sertraline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline + Enhanced Medication Management (SERT + EMM)
Study: 32446716
Drug: Non-selective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blockers (NSBBs)
Study: 32447411
Drug: Melanoma targeted
Normalized name: melanoma vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melanoma targeted radionuclide therapy (TRT)
Study: 32447421
Drug: PG-11047, 60-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG-11047, 60-min intravenous infusions, doses ranging from 50 to 750 mg, administered on days 1, 8, and 15 of a 28-day cycle
Study: 32448349
Drug: 2-hour plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hour plasma glucose (2-h PG) after a 75-g oral glucose tolerance test
Study: 32448380
Drug: Adjusted HLH-2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted HLH-2004 criteria cutoffs (hyperferritinemia to 3000 μg/L and fever to 38.2 °C)
Study: 32448701
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D status (25-hydroxyvitamin D levels <20 ng/mL)
Study: 32448902
Drug: Raltegravir 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 12 mg/kg twice daily (administered after crushing)
Study: 32449684
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Therapy (CBT) plus Treatment-As-Usual (TAU)
Study: 32449684
Drug: Group Exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Exercise plus Treatment-As-Usual (TAU)
Study: 32449684
Drug: Wait-listing to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-listing to receive Treatment-As-Usual (TAU) only
Study: 32449927
Drug: Optimized criteria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized criteria (PAC >20 ng/dL, PRC <2.5 μIU/mL, hypokalemia)
Study: 32451120
Drug: Efavirenz 400
Normalized name: efavirenz 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 400 mg once daily for CYP2B6 516 GG genotype
Study: 32451120
Drug: Efavirenz 300
Normalized name: efavirenz 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 300 mg once daily for CYP2B6 516 GT genotype
Study: 32451120
Drug: Efavirenz 100
Normalized name: efavirenz 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 100 mg once daily for CYP2B6 516 TT genotype
Study: 32451120
Drug: Efavirenz 800
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 800 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GG genotype
Study: 32451120
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 GT genotype
Study: 32451120
Drug: Efavirenz 200
Normalized name: efavirenz 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 200 mg once daily for HIV/tuberculosis co-infected patients with CYP2B6 516 TT genotype
Study: 32451120
Drug: Rifampicin co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin co-administration
Study: 32451615
Drug: Daclizumab beta
Normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab beta 150 mg subcutaneously every 4 weeks for up to 6 years
Study: 32451615
Drug: Daclizumab beta
Normalized name: Daclizumab beta
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab beta treatment
Study: 32452555
Drug: Promoting the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promoting the administration of antenatal corticosteroids (ACS)
Study: 32453640
Drug: DA-EPOCH-R therapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R therapy (3 cycles for low-risk, 6 cycles with CNS prophylaxis for high-risk)
Study: 32453841
Drug: Anti-CD19 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD19 CAR T-cell therapy
Study: 32453841
Drug: Allogeneic hematopoietic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic hematopoietic stem cell transplant (allo-HSCT) after CAR T-cell therapy
Study: 32458180
Drug: Overall patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall patient satisfaction with ablation therapy
Study: 32458378
Drug: Vericiguat co-administered
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vericiguat co-administered with various drugs (omeprazole, magnesium/aluminum hydroxide, ketoconazole, rifampicin, mefenamic acid, midazolam, warfarin, digoxin, sacubitril/valsartan, aspirin, sildenafil)
Study: 32459419
Drug: Recreational drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recreational drug use before pregnancy (33.8%) vs during pregnancy (1.1% at visit 2, 0.7% at visit 3, 0.4% at visit 4)
Study: 32459639
Drug: Wearable blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable blood pressure monitoring device (Health Gauge), daily self-monitoring of blood pressure and monthly evaluation for weight gain from 20 weeks of gestation until delivery
Study: 32459957
Drug: MEDI3726 (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3726 (an Anti-Prostate-Specific Membrane Antigen Pyrrolobenzodiazepine Antibody-Drug Conjugate)
Study: 32460197
Drug: Crizotinib treatment
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib treatment
Study: 32461262
Drug: 0.2 µg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 µg/day fluocinolone acetonide (FAc) implant
Study: 32463152
Drug: Cabozantinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (100 mg/day, later reduced to 60 mg/day)
Study: 32464183
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with obesity and insulin resistance
Study: 32464281
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg/day for 1 year plus loperamide prophylaxis (days 1-28)
Study: 32464281
Drug: Neratinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib dose escalation (DE)
Study: 32464282
Drug: R-CODOX-M/R-IVAC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CODOX-M/R-IVAC chemotherapy (alternating cycles of CODOX-M and IVAC plus eight doses of rituximab)
Study: 32464282
Drug: R-CODOX-M/R-IVAC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CODOX-M/R-IVAC chemotherapy
Study: 32464368
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (sRT) with hormonal therapy
Study: 32464368
Drug: Salvage radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiation therapy (sRT) without hormonal therapy
Study: 32466779
Drug: First-line aromatase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line aromatase inhibitor (AI) treatment
Study: 32467323
Drug: Alteplase 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 0.9 mg/kg intravenously
Study: 32467765
Drug: Anti-IL5/IL5R therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IL5/IL5R therapy
Study: 32467765
Drug: Anti-IgE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-IgE therapy
Study: 32467765
Drug: Biological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological therapy (general)
Study: 32468741
Drug: Vorico® Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorico® Injection (test formulation)
Study: 32468741
Drug: Vfend® IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vfend® IV (reference formulation)
Study: 32469092
Drug: Dupilumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab as add-on therapy to maximal standard of care
Study: 32469129
Drug: Wearable fitness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable fitness device (Garmin Vivoactive HR) and exercise prescription (150 min of moderately to vigorous exercise per week)
Study: 32469185
Drug: Tepotinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib (500 mg once daily)
Study: 32469386
Drug: FOLFIRINOX (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX (fluorouracil 400 mg/m2 bolus, 2400 mg/m2 over 46 hours; leucovorin 400 mg/m2; irinotecan 180 mg/m2; oxaliplatin 85 mg/m2) with trastuzumab for ERBB2-positive patients (6 mg/kg loading dose, then 4 mg/kg every 14 days)
Study: 37290461
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg orally once daily)
Study: 32471030
Drug: Nivolumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (12 patients), combination of nivolumab and ipilimumab (1 patient), pembrolizumab (remaining patients)
Study: 32471909
Drug: Hyperglycemic condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic condition (second scanning session, 20 mmol/L [360 mg/dL])
Study: 32471990
Drug: Targeted fusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted fusion therapies
Study: 32472007
Drug: Standardised frankincense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised frankincense extract (SFE) taken daily for eight months
Study: 32472319
Drug: CDX-014 administered
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDX-014 administered intravenously at doses ranging from 0.15 to 2.0 mg/kg every 2 or 3 weeks until progression or unacceptable toxicity.
Study: 32474892
Drug: JE-CV (live-attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV (live-attenuated Japanese encephalitis chimeric virus vaccine)
Study: 32476520
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and dexamethasone therapy with doses adjusted based on creatinine clearance (10 mg for moderate RI, CrCl 30-60 mL/min)
Study: 32476520
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and dexamethasone therapy
Study: 32477016
Drug: RADREMI dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: RADREMI dosing (SRS doses of 18 Gy for 0-2 cm lesions, 14 Gy for 2.1-3 cm lesions, and 12 Gy for 3.1-4 cm lesions)
Study: 32477016
Drug: RADREMI dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: RADREMI dosing
Study: 32478195
Drug: Exubera (EXU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exubera (EXU; insulin human [rDNA origin] Inhalation Powder)
Study: 32478814
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg
Study: 32478814
Drug: Nivolumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 0.5 mg/kg
Study: 32479189
Drug: Pembrolizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab with weekly cisplatin-based chemoradiotherapy
Study: 32479608
Drug: Artefenomel 200-mg
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 200-mg dose
Study: 32479608
Drug: Artefenomel 300-mg
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artefenomel 300-mg dose (predicted)
Study: 32480059
Drug: LDL-C <
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C < 100 mg/dL (70-99 mg/dL)
Study: 32480059
Drug: LDL-C <
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C < 70 mg/dL
Study: 32482616
Drug: Conventional dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual antiplatelet therapy (DAPT)
Study: 32482616
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after one-month DAPT
Study: 32484435
Drug: Topical dithranol
Normalized name: Zithranol
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dithranol (anthralin)
Study: 32484552
Drug: Suvorexant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (10 mg for 1 week, titrated to 20 mg for 2 weeks)
Study: 32485203
Drug: Ketamine (esketamine)
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ketamine (esketamine) treatment for TRD
Study: 32486385
Drug: BI 860585
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 860585 monotherapy (5-300 mg/day)
Study: 32486385
Drug: BI 860585
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 860585 (40-220 mg/day) with 25 mg/day exemestane
Study: 32486385
Drug: BI 860585
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 860585 (80-220 mg/day) with 60-80 mg/m2 paclitaxel
Study: 32487218
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy and radiotherapy
Study: 32487218
Drug: CTC patterns
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC patterns following treatment
Study: 32487542
Drug: Trifluridine/tipiracil 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil 35 mg/m²
Study: 32487574
Drug: Chemotherapy (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (first-line or third-line)
Study: 32487574
Drug: Questionnaires including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Questionnaires including EORTC-QLQ-C30, Decisional Conflict Scale, Control Preferences Scale, Quality-Quantity Questionnaire, treatment expectations, EORTC financial toxicity items, Work Ability Index, FACT-G items, Decisional Regret Scale
Study: 32487642
Drug: CTC/ctDNA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC/ctDNA combination assay
Study: 32488055
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment strategy (TTS) guided by ex vivo drug sensitivity/resistance profiling (DSRP) and targeted next-generation sequencing (tNGS)
Study: 32488055
Drug: Tailored treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored treatment strategy (TTS)
Study: 32488989
Drug: Sapanisertib 40
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 40 mg single dose
Study: 32489718
Drug: Algorithm for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm for measuring problem prescription opioid use
Study: 32489805
Drug: Antithrombotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic treatment
Study: 32489805
Drug: Antiplatelet drugs
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet drugs (APD)
Study: 32489805
Drug: Overall anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall anticoagulation therapy patterns
Study: 32492069
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (injection frequency ≤4)